Semaglutide oral liquid: clearing up what this product actually is

The myth worth correcting first: semaglutide does not come as a liquid

Search results for "semaglutide oral liquid" often surface because people conflate several different ideas: the injectable pen (a liquid inside a cartridge), compounded semaglutide preparations sold from unregulated sources, and the genuine oral tablet. None of these is a semaglutide oral liquid in any licensed sense.

The MHRA (the UK medicines regulator) has approved two forms of semaglutide for weight management: the subcutaneous injection sold as Wegovy, and the tablet approved in June 2026, making the UK the first country in Europe to license an oral GLP-1 medicine for weight loss. The tablet uses an absorption enhancer called SNAC to allow semaglutide to cross the stomach lining; it is a solid pill, swallowed whole.

Compounded or "pharmacy-prepared" semaglutide liquids do exist in some countries, and reports of their sale in the UK via social media and unlicensed online sellers have led to MHRA warnings. The regulator seized medicines worth around £45 million in 2025 alone, including counterfeit tirzepatide pens and unlicensed semaglutide preparations. If a product is presented as a semaglutide liquid for injection or ingestion and is not dispensed through a GPhC-registered pharmacy against a valid prescription, it carries serious risks, contents are unverified, and some seized products have contained harmful substances. You can read about the NHS patient information for semaglutide to see what the licensed forms look like.

The practical takeaway: if you are searching for an oral semaglutide option, the answer is a tablet, not a liquid, and you can find out more about semaglutide oral drops to understand why that particular format has no licensed place in UK treatment. That distinction matters.

How the oral semaglutide tablet is actually taken

The Wegovy tablet schedule starts at 1.5 mg once daily. From there, the prescriber moves the patient up through 4 mg and 9 mg to the 25 mg maintenance dose, spending at least a month at each level. The slow escalation is deliberate, it reduces gastrointestinal side effects, which are the most commonly reported issue with oral semaglutide.

Timing is unusually specific. The tablet must be the first thing you take in the morning, with no more than around 120 ml of plain water, on a completely empty stomach. You then wait at least 30 minutes before eating, drinking anything else (including coffee), or taking other oral medicines. This is not a suggestion; it is how the absorption mechanism works. Miss that window and absorption drops significantly.

For anyone thinking about how this fits into a routine, it genuinely does reward consistency, whether that means setting a daily alarm or leaving the packet somewhere obvious, like next to the bathroom tap. Some patients find the no-food window easier on non-working days; others find a Monday-to-Friday routine easier to maintain around work. Your prescriber can help you think through what works. You can explore how oral semaglutide compares to the injection if you are weighing up which form suits your life better.

No refrigeration is required, which does make the tablet genuinely more practical for travel than the injection. The MHRA-approved patient information leaflet, available via the electronic Medicines Compendium, carries the full storage and handling details.

Who this tablet is licensed for, and what the trial evidence shows

The Wegovy tablet is licensed for adults with a BMI of 30 or above, or a BMI between 27 and 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. It is taken alongside a reduced-calorie diet and increased physical activity, the tablet is part of a broader approach, not a standalone fix.

The phase 3 evidence comes from the OASIS 4 trial, which followed 307 adults with obesity or overweight and at least one weight-related condition over 64 weeks. Average weight loss was around 13.6% compared with around 2.4% on placebo. Among participants who adhered fully to the treatment, average loss reached approximately 17%, though that figure applies specifically to that adherent group, not to all participants. Most side effects were gastrointestinal: nausea, diarrhoea, and constipation, reported in about 74% of tablet users versus 42% on placebo. These were generally mild to moderate and tended to ease as treatment continued.

The Wegovy tablet is not currently available on the NHS, a NICE technology appraisal would be required before that pathway opens. Private prescription is the only current route. Our overview of semaglutide tablet options covers the full picture, and our page on semaglutide oral tablets goes into further detail on how the licensed solid-dose form works day to day, and pricing context for the Wegovy pill explains what a legitimate private prescription typically includes. For anyone curious about how the oral and injectable options compare on effectiveness, the Wegovy pill hub pulls together the key evidence.

What this means if you are considering treatment

The search for a semaglutide oral liquid often comes from a genuine place: people want an effective weight-loss medicine that does not involve injections. The oral tablet now makes that possible through a legitimate, MHRA-approved route. What it does not make possible is bypassing a clinical assessment.

Semaglutide, in any form, is a prescription-only medicine. A prescriber reviews your medical history, current medicines, BMI, and any conditions before deciding whether it is appropriate and at what dose. That step protects you, interactions with some medications, a history of pancreatitis, and certain other conditions can make this medicine unsuitable. Our clinical team at nume handles that review personally, the same day you submit your consultation, every time.

If you have questions before starting, our FAQs cover a range of common concerns, from what happens at the first consultation to how repeat prescriptions are managed. And if you want a broader look at the weight-loss treatments we offer, the treatment overview sets out what is available and for whom. When you are ready, you can speak to our prescribers through a free consultation, with no obligation and no subscription to sign up to.